Kevin has made over … News; Careers; Investors; USA; Professionals. Boston Scientific executives and other stock owners filed with the SEC include: Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens, Stocks and cryptocurrency portfolio tracker. As of 3 March 2020 Kevin still owns at least 83,388 units of Boston Scientific stock. “It is an honor and privilege to be joining Michael and the Aldevron team at this pivotal time,” Ballinger said. As a leadership team we are focused on high performance to benefit patients, clinicians and shareholders. Senior Vice President and President, Interventional Cardiology As one of Boston Scientific’s most tenured executives, Ballinger helped advance the company’s market leadership, growing the IC division into a $3 billion global business. “We are thrilled to appoint Kevin as CEO and know that he is the right person to help build on this momentum. Ballinger joins Aldevron from Boston Scientific (NYSE: BSX), a global medical device leader whose products are used in a broad range of interventional medical specialties. The estimated Net Worth of Kevin J. Ballinger is at least $12 Million dollars as of 3 March 2020. Skip to main content Skip to search Skip to product navigation. . Use of Data / Disclaimer. He brings 25 years of operating experience, including serving the past nine years as Executive Vice President and Global President of Boston Scientific’s largest division, Interventional Cardiology (IC). On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $2,741,700. See Kevin J Ballinger's compensation, career history, education, & memberships. Prior to his current role, he held a variety of engineering and general management positions within Boston Scientific’s Interventional Cardiology business unit, including overseeing the development of the company’s first drug-eluting stents. Medical Specialties; Electrophysiology; Kevin J Ballinger is Chief Executive Officer at Aldevron LLC. in Mechanical Engineering from Michigan Tech University and an MBA from the University of Minnesota. Kevin Ballinger owns over 3,303 units of Boston Scientific stock worth over $3,444,758 and over the last 8 years Kevin sold BSX stock worth over $8,536,213. www.vbprofiles.com is now www.topionetworks.com. He brings 25 years of operating experience, including serving the past nine years as Executive Vice President and Global President of Boston Scientific’s largest division, Interventional Cardiology (IC). The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The largest trade Kevin's ever made was exercising 111,807 units of Boston Scientific stock on 27 April 2016 worth over $1,016,326. The information shown here is a reporting of information included in the company's proxy statement. I look forward to helping the company continue to grow its capabilities as developments in science rapidly advance. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. ", Commenting on the leadership appointment, Chambers stated, “This is a new era for Aldevron. The most recent stock trade was executed by David A Pierce on 1 October 2020, trading 2,282 units of BSX stock currently worth $87,994. Corporate News, Kevin Ballinger to Assume CEO Role at Aldevron; Michael Chambers to become Executive Chairman. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. Aldevron is well-positioned to continue our leadership position in manufacturing critical nucleic acids and proteins in support of our clients, who are creating technologies to help millions of people.”, “Speaking on behalf of the board, Michael has helped shape the industry as we know it today,” said Sheri McCoy, Non-Executive Chairman of the board. Ballinger has more than 17 years of interventional cardiology experience. I am excited to partner with Kevin, who has the ideal combination of experience and drive, and together serve our clients during this important next phase in our company’s history. This new partnership between Michael and Kevin will help the company unlock new opportunities in the biotech industry.”, Topics: Chambers initiated the transition to allow him to focus on innovation, corporate strategy and working with clients and industry thought leaders to develop new technologies that enable genetic medicine. He will provide a strong focus on Aldevron’s core values and its commitment to clients and their work. “Genetic medicine is vital, now more than ever, and Aldevron is a key partner in helping to bring life-changing therapies to countless patients whose lives depend on biotechnology breakthroughs. Meet Boston Scientific's Executive Committee and Board Of Directors. Ballinger will assume day-to-day operational leadership of Aldevron, facilitating the company’s rapid growth. Over the last 15 years, insiders at Boston Scientific have traded over $780,704,586 worth of Boston Scientific stock and bought 1,373,972 units worth $15,182,039 Ballinger joins Aldevron from Boston Scientific (NYSE: BSX), a global medical device leader whose products are used in a broad range of interventional medical specialties. Curated profile of Kevin Ballinger, Senior Vice President and President, Interventional Cardiology, Boston Scientific including career history, news and intelligence, portfolio companies and investments. Kevin Ballinger BSX stock SEC Form 4 insiders trading. Skip to main content Skip to search Skip to product navigation You can see the complete history of Kevin Ballinger stock trades at the bottom of the page. In this role, he is responsible for developing and bringing to market innovative solutions that diagnose and treat coronary artery disease and cardiac valve disorders. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. Kevin has made over 61 trades of the Boston Scientific stock since 2013, according to the Form 4 filled with the SEC. Thank you for your continued support. On average, Kevin trades about 15,423 units every 38 days since 2013. The most active insiders traders include Peter M Nicholas, John E Abele, and Michael F Mahoney. Kevin Ballinger is Senior Vice President and Global President, Interventional Cardiology for Boston Scientific and a member of its Executive Committee. We look forward to providing you with even more cutting-edge market research, as Topio Networks. Most recently Kevin exercised 3,303 units of BSX stock worth $136,447 on 3 March 2020. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA. Attracting one of med-tech’s most accomplished executives, Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13, 2020. at, Senior Vice President and President, Interventional Cardiology, University of Minnesota - Carlson School of Management. Boston Scientific's Executive Committee and Board Of Directors are focused on high performance to benefit patients, clinicians and shareholders. Attracting one of med-tech’s most accomplished executives, Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13, 2020. Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. A native of Minnesota, Ballinger earned his BS in Mechanical Engineering from Michigan Technological University, and his MBA from the University of Minnesota’s Carlson School of Management. Aldevron’s co-founder, Michael Chambers, has been named Executive Chairman of the board. Same platform but with new and improved features. Ballinger earned a B.S. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions.